- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 262 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- July 2024
- 100 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- May 2024
- 607 Pages
Global
From €2346EUR$2,468USD£1,971GBP
€3128EUR$3,290USD£2,628GBP
- Report
- March 2025
Global
From €4658EUR$4,900USD£3,913GBP
- Report
- January 2025
- 150 Pages
Global
From €4421EUR$4,650USD£3,714GBP
- Report
- March 2025
- 197 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 196 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 190 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- September 2024
- 150 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- August 2024
- 142 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- March 2025
- 89 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 194 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- December 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 184 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- July 2024
- 185 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- April 2024
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- July 2024
- 141 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- June 2024
- 145 Pages
Global
From €2377EUR$2,500USD£1,997GBP

The Cancer Liquid Biopsy market is a subset of the Diagnostics industry that focuses on the use of liquid biopsies to detect and monitor cancer. Liquid biopsies are non-invasive tests that use a sample of blood, urine, or other bodily fluid to detect cancer cells or genetic material associated with cancer. This type of biopsy can provide information about the type and stage of cancer, as well as the presence of mutations that may affect treatment options. Liquid biopsies are increasingly being used to monitor cancer progression and response to treatment, as well as to detect cancer recurrence.
Some companies in the Cancer Liquid Biopsy market include Guardant Health, Exosome Diagnostics, Freenome, and Biocept. Show Less Read more